Study results published in The Journal of Translational Medicine
PORTLAND, Ore., December 3, 2019 — Nobilis Therapeutics, Inc. announced today the results of its preclinical study assessing the effects of its NBTX-001, a xenon-based therapeutic, in an animal model of Autism Spectrum Disorder. The article titled “Beneficial effects of xenon inhalation on behavioral changes in a valproic acid-induced model of autism in rats” was published in The Journal of Translational Medicine.
The study consisted of a two series of experiments with a battery of behavioral tests aimed to evaluate locomotion, anxiety- and depression-like behavior, and social behavior in animals with and without autism. The results were positive in both groups and in the latter group they clearly demonstrated improvement in social behavior.
“There are very few treatment options for patients with Autism Spectrum Disorder,” said Vlad Bogin, CEO of Nobilis Therapeutics. “This is the first study demonstrating that a Xenon-based therapeutic can have a positive effect on this devastating disease.” “We believe that our drug’s multimodal mechanism of action has a positive effect on the excitatory-inhibitory balance within the CNS that should be rapidly translated into clinical research,” concluded Dr. Bogin.
About Nobilis Therapeutics
Nobilis Therapeutics is a biotechnology company that is focused on development and commercialization of proprietary inhalation-based treatments using portable controlled device administration of inert gases. The Company has filed multiple patents on the use of inert gases for treatment of a variety of psychiatric, neurodegenerative and other diseases and leverages the experience of its international team that has studied this technology in the treatment of over 2500 patients for conditions ranging from panic attacks to substance abuse. The Company has filed an IND to initiate a phase IIb/III clinical trial to evaluate the efficacy of NBTX-001, its lead compound, for the treatment of patients with PTSD.
Vlad Bogin, MD, FACP
Tel: (971) 229-1679